Literature DB >> 32736331

Ceftriaxone pharmacokinetics by a sensitive and simple LC-MS/MS method: Development and application.

L Herrera-Hidalgo1, M V Gil-Navarro2, S Dilly Penchala3, L E López-Cortes4, A de Alarcón5, R Luque-Márquez5, L F López-Cortes5, A Gutiérrez-Valencia5.   

Abstract

Ceftriaxone is a third-generation cephalosporin, worldwide use as a first-line treatment for several infections, including life-threatening infections as meningitis or endocarditis. Nowadays, ceftriaxone use is changing, embracing high-dose schemes, new populations treated and requirement of dose individualization and optimization. These reasons warranted the development of new sensitive assays. This study aimed to develop and validate a fast and handy bioanalytical method for the quantification of ceftriaxone in human plasma covering a broad range of concentrations. The analysis was performed using high-performance liquid chromatography coupled to tandem mass spectrometry. Sample preparation was based on protein precipitation with acetonitrile followed by centrifugation. Chromatography separation was performed on Phenomenex Luna C18 column (5 μm, 150 × 2.0 mm) and a mobile phase consisting of 70 % of mobile phase A (10 mM of ammonium acetate and 1% formic acid in purified water) and 30 % mobile phase B (0.1 % formic acid in acetonitrile) at a flow rate of 500 μl/min on an isocratic program. Both the analyte and the internal standard were quantified using the positive electrospray ionization (ESI) mode within a single runtime of 5.00 min. The method was validated following the U.S. Food and Drug Administration guidelines over the concentration range of 3-1000 μg/mL. The within-run and between-run precision and accuracy were <15 %, and therefore met the standard regulatory acceptance criterion. In conclusion, a sensitive and robust LC-MS/MS method was developed for a fast quantitation of ceftriaxone concentrations in plasma samples with multiples applications in research and clinical therapeutic drug monitoring.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ceftriaxone; Development; LC–MS/MS; Pharmacokinetics; Validation

Year:  2020        PMID: 32736331     DOI: 10.1016/j.jpba.2020.113484

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

Authors:  Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 2.  A Review of Methods for Removal of Ceftriaxone from Wastewater.

Authors:  Petro Karungamye; Anita Rugaika; Kelvin Mtei; Revocatus Machunda
Journal:  J Xenobiot       Date:  2022-08-02

3.  Determination of ceftriaxone in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Thamrong Wongchang; Markus Winterberg; Joel Tarning; Natthida Sriboonvorakul; Sant Muangnoicharoen; Daniel Blessborn
Journal:  Wellcome Open Res       Date:  2021-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.